Dosage escalation of intravenous cyclophosphamide in cats with cancer

Moore, Antony S.; Frimberger, Angela E.; Chan, Catherine M.

doi:10.1016/j.tvjl.2018.10.003

Cited by 7 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, vincristine is associated with mild toxicity. Cyclophosphamide is a nitrogen mustard agent that is commonly combined in multiagent chemotherapeutic protocols for dogs and cats [28]. On the other hand, FeLV can infect hematopoietic stem cells in the bone marrow causing neutropenia and secondary infection infected cats [29].…”

Section: Discussionmentioning

confidence: 99%

Effects of Chemotherapy on Hematological Parameters and CD4+/CD8+ Ratio in Cats with Mediastinal Lymphoma and Seropositive to Feline Leukemia Virus

Jaroensong

Piamwaree

Suttasathuchana

2022

Animals

View full text Add to dashboard Cite

The objective of this study was to evaluate the effect of the COP chemotherapeutic protocol on hematological parameters, CD4+/CD8+ ratio, and the mortality of 18 client-owned FeLV-infected cats with mediastinal lymphoma. The complete blood count, creatinine, alanine aminotransferase, and CD4+/CD8+ ratio were measured four times before treating with chemotherapy in the 1st, 2nd, 3rd, and 4th weeks. The white blood cell (WBC) counts at the 1st week were significantly different from the 2nd, 3rd, and 4th inductions (p = 0.0075, p = <0.0001, and p = 0.0271, respectively). The neutrophils at the 1st week were significantly different from the 2nd and 3rd inductions (p = 0.0179, and p < 0.0001, respectively). The packed cell volume (PCV) at the 1st week was significantly differed from the 2nd, 3rd, and 4th induction times (p = 0.0029, p = 0.0006, and p = 0.0029, respectively. The mean corpuscular volume (MCV) at the 1st week was significantly different from the 4th week (p = 0.0145). We found that chemotherapy did not cause any significant change in the CD4+/CD8+ ratio (p-value 0.7407). The Kaplan–Meier curves showed the median survival time (MST) for the cats with a CD4+/CD8 ratio of less than 1 after the 1st week of chemotherapy was 134 days. This suggested that COP chemotherapy was a safe treatment for FeLV-infected cats with mediastinal lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Chemotherapy on Hematological Parameters and CD4+/CD8+ Ratio in Cats with Mediastinal Lymphoma and Seropositive to Feline Leukemia Virus

Jaroensong

Piamwaree

Suttasathuchana

2022

Animals

View full text Add to dashboard Cite

show abstract

“…Recently, the recommended dosage for single agent CPA in combination with prednisolone in cats with cancer was reported to be 460 mg/m 2 q3 weeks (153 mg/m 2 /week). 20 Therefore, we should have used a higher initial dose of CPA. Although melphalan is one of the treatments used in plasma cell tumours, it was decided not to use this medication owing to reported increased side effects than CPA in cats with MRD.…”

Section: Discussionmentioning

confidence: 99%

Primary duodenal plasmacytoma with associated primary (amyloid light-chain) amyloidosis in a cat

Tamura

Chambers²,

Neo

et al. 2020

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 14-year-old spayed female American Shorthair cat was presented with weight loss and a palpable abdominal mass. Abdominal ultrasound and CT revealed a duodenal mass with suspected perforation and an enlarged jejunal lymph node. Cytological evaluation from a fine-needle aspiration of the abdominal mass displayed many atypical round cells, some with a small amount of light pink material at the cellular edge. The duodenal mass was surgically removed, and was diagnosed as a plasma cell tumour immunohistochemically positive for CD79 alpha, IgA and lambda immunoglobulin light chains. In addition, amyloidosis was detected. PCR to assess the antigen receptor rearrangement of the tumour cells showed a monoclonal rearrangement of the immunoglobulin heavy chain gene. Postoperatively, the cat received chemotherapy with cyclophosphamide and prednisolone. Owing to progressive enlargement of the jejunal lymph node, different chemotherapy protocols were used sequentially, namely chlorambucil, lomustine and L-asparaginase. However, the cat died 96 days after the initial diagnosis. Post-mortem examination confirmed systemic dissemination of tumour cells. The cause of death was considered to be a result of a complication of the tumour itself and associated amyloidosis. Relevance and novel information This patient was diagnosed with a primary duodenal plasmacytoma, and primary (amyloid light-chain) amyloidosis. In cats, intestinal plasmacytoma is rarely reported and associated amyloidosis is an uncommon feature, when compared with humans. To our knowledge, this is the first clinical report of duodenal plasmacytoma in a cat. The present report shows that feline plasmacytomas should be included in the differential diagnosis of a duodenal mass.

show abstract

“…15 Cats have been shown to tolerate higher cyclophosphamide dosages than dogs; an appropriate dosage is 460 mg/m 2 . 16,17 Although this dosage of cyclophosphamide has been shown to be safe in cats, it is unclear whether incorporating this dosage, and incorporating other drugs as suggested above, into combination chemotherapy protocols would provide better outcomes (improved remission rates and lower toxicity risk) for cats with alimentary lymphoma. The intent of this study was to retrospectively evaluate such a protocol (VACP protocol) for efficacy and toxicity and to identify prognostic factors that predict patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Treatment of feline intermediate to high‐grade alimentary lymphoma: A retrospective evaluation of 55 cats treated with the VAPC combination chemotherapy protocol (2017–2021)

Moore,

Frimberger

2023

Vet Comparative Oncology

View full text Add to dashboard Cite

The most commonly utilized protocols to treat lymphoma in cats employ vincristine, cyclophosphamide and prednisone; with additional drugs sometimes used including L‐asparaginase and doxorubicin. Medical records were reviewed for 55 cats with alimentary lymphoma treated with a novel multiagent protocol using prednisolone, L‐asparaginase, doxorubicin, vinblastine instead of vincristine, a higher dosage of cyclophosphamide and oral procarbazine (VAPC protocol). Outcomes evaluated were response to therapy, toxicity and progression‐free survival (PFS). Grade 3 or 4 neutropenia was the most common treatment‐related reason for chemotherapy dosage adjustment, occurring in 8 of 52 cats receiving vinblastine, 7 of 55 cats receiving cyclophosphamide and 1 of 40 cats receiving doxorubicin, but febrile neutropenia was identified in only two cats. Of 38 cats receiving chemotherapy for measurable disease, 26 (68.4%) achieved complete response (CR). Three cats achieved a partial response and 9 cats failed to achieve a remission. There were no identified factors influencing whether a cat was likely to achieve CR. For all 55 cats (including those receiving chemotherapy and surgery), median PFS was 184 days with 1, 2 and 3‐year survival rates of 35.4%, 26.5% and 26.5%, respectively. On multivariate analysis, 40 cats that achieved CR had a median survival time of 341 days (78 days for PR, 45 days for NR); PFS times were also significantly affected by lymphocyte:monocyte L:M ratio (>3.4 = 700 days vs. ≤3.4 = 126 days) and B‐cell versus T‐cell phenotype (220 days vs. 42 days, respectively).

show abstract

Dosage escalation of intravenous cyclophosphamide in cats with cancer

Cited by 7 publications

References 16 publications

Effects of Chemotherapy on Hematological Parameters and CD4+/CD8+ Ratio in Cats with Mediastinal Lymphoma and Seropositive to Feline Leukemia Virus

Effects of Chemotherapy on Hematological Parameters and CD4+/CD8+ Ratio in Cats with Mediastinal Lymphoma and Seropositive to Feline Leukemia Virus

Primary duodenal plasmacytoma with associated primary (amyloid light-chain) amyloidosis in a cat

Treatment of feline intermediate to high‐grade alimentary lymphoma: A retrospective evaluation of 55 cats treated with the VAPC combination chemotherapy protocol (2017–2021)

Contact Info

Product

Resources

About